Unknown

Dataset Information

0

Development and validation of next generation sequencing based 35-gene hereditary cancer panel.


ABSTRACT: Background:Understanding the genetic basis of cancer risk is a major international endeavor. The emergence of next-generation sequencing (NGS) in late 2000's has further accelerated the discovery of many cancer susceptibility genes. The use of targeted NGS-based multigene testing panels to provide comprehensive analysis of cancer susceptible genes has proven to be a viable option, with the accurate and robust detection of a wide range of clinically relevant variants in the targeted genes being crucial. Methods:We have developed and validated a targeted NGS-based test for hereditary cancer risk assessment using Illumina's NGS platform by analyzing the protein-coding regions of 35 hereditary cancer genes with a bioinformatics pipeline that utilizes standard practices in the field. This 35-gene hereditary cancer panel is designed to identify germline cancer-causing mutations for 8 different cancers: breast, ovarian, prostate, uterine, colorectal, pancreatic, stomach cancers and melanoma. The panel was validated using well-characterized DNA specimens [NIGMS Human Genetic Cell Repository], where DNA had been extracted using blood of individuals whose genetic variants had been previously characterized by the 1000 Genome Project and the Coriell Catalog. Results:The 35-gene hereditary cancer panel shows high sensitivity (99.9%) and specificity (100%) across 4820 variants including single nucleotide variants (SNVs) and small insertions and deletions (indel; up to 25?bp). The reproducibility and repeatability are 99.8 and 100%, respectively. Conclusions:The use of targeted NGS-based multigene testing panels to provide comprehensive analysis of cancer susceptible genes has been considered a viable option. In the present study, we developed and validated a 35-gene panel for testing 8 common cancers using next-generation sequencing (NGS). The performance of our hereditary cancer panel is assessed across a board range of variants in the 35 genes to support clinical use.

PROVIDER: S-EPMC7189534 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5769462 | BioStudies
2019-01-01 | S-EPMC6547505 | BioStudies
| S-EPMC8314385 | BioStudies
| S-EPMC5289469 | BioStudies
| S-EPMC7326311 | BioStudies
| S-EPMC7288470 | BioStudies
| S-EPMC6093350 | BioStudies
| S-EPMC4225457 | BioStudies
| S-EPMC5599323 | BioStudies
| S-EPMC5209723 | BioStudies